FDA’s Crawford Off The Mat: Nomination Revived After Investigation Closes
Executive Summary
The conclusion of the HHS Inspector General's investigation into allegations against FDA Commissioner nominee Lester Crawford removes one roadblock in his confirmation process
You may also be interested in...
A Brief But Memorable Tenure: Former US FDA Commissioner Lester Crawford Dies At 83
Crawford’s time as permanent FDA commissioner lasted less than three months and ended in scandal, but with that stint and his longer stretches as acting commissioner, he oversaw the agency through several historic moments that continue to influence the current regulatory environment.
Commissioner Von Eschenbach: NCI Director Named Acting Head Of FDA
National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner
Crawford’s First Business After Confirmation: Brief Senators On Mifeprex
FDA Commissioner Lester Crawford's first business following his confirmation was to brief members of Congress about reports of deaths in patients using Danco Laboratories' abortifacientMifeprex